rchen@fordham.edu

Vadim Mezrin (Graduated, May 2005)

Vadim is working on complex option pricing models. He has developed an option pricing model when the returns of the underlying asset present serial correlation.

Hsuan-chu Lin (Graduated, May 2006)

Hsuan-Chu is teaching at the Cheng-Kung University in Tainan, Taiwan (only 60 miles from his home town Kaoshung). He is working on three papers - Going concern audit, Structural agency problem, and Option lower bounds.

Bo Liu (Gradulated, May 2006)

Bo wrote his dissertation on inflation linked bonds (TIPS). He empirically tested a two-factor affine model (with a closed form solution to TIPS) and identified the inflation risk premiums embedded in TIPS. He is currently working at Citi Group.

Xiolin Cheng (Graduated, October 2006)

Xiaolin has defended her dissertation back in July and will start working for Moody's on October 1. Her dissertation has won the outstanding dissertation award at the 2005 FMA and was presented at the special doctoral session. The CDS paper we wrote with Bo and Frank has been accepted by JFQA. She is currently working at Morgan Stanley.

Ronald Sverdlove (Graduated, October 2007)

Co-guided by Prof. Ravid and myself, Ron is working on theoretical and empirical corporate bond modeling issues. Theoretically Ron is working on optimal debt contracting. Empirically Ron is studying the liquidity problem in CDS contracts and also potential issues with matrix data. He is also working on film related issues. He defended his proposal in April. Ron will present two papers in FMA 2006. Ron's dissertation has won the best dissertation in fixed income at the 2006 FMA. Ron is teaching at NJIT.

Mary Kay Scucci (Graduated, October 2007)

Co-guided by Dr. Hassan and myself, Mary Kay did her dissertation on health economics. She applied the real option methodology to explain health costs. She was a former Chief Financial Officer at Bear Sterns Asset Management.

Durga Panda (Graduated, May 2010)

Mr. Panda is also interested in general asset pricing. He has finished two papers: How to use option pricing model to come up ex ante returns to perform asset pricing tests, and the term structure of expected returns. He is working on the third essey. He has passed the proposal defense and is expected to defend his dissertation in early 2010. He was among very few selected to 2009 FMA dissertation consortium.

Michael Imerman (Graduated, May 2011)

Mr. Imerman is working on capital structural equilibrium and firm valuation under the joint supervision of Dr. Soprazetti and myself. He has finished one working paper using the Geske model for regulatory capital and is working on other projects.

Te-Chien (David) Lo (Graduated, May 2012)

Te-Chien is working on microstructure research using asset pricing theories. He intends to bridge the two strings of research.

updated June 9, 2012.

Order Zithromax

order Zithromax

Zithromax is used to treat many different types of infections caused by bacteria, such as respiratory infections, skin infections, ear infections, and sexually transmitted diseases.Zithromax may also be used for purposes not listed in this medication guide.

ZITHROMAX

To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX® (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

The extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of infections in these additional body sites, the clinical significance of these tissue concentration data is unknown.

Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, only very low concentrations were noted in cerebrospinal fluid (less than 0.01 µg/mL) in the presence of non-inflamed meninges.

Following oral administration of a single 1200 mg dose (two 600 mg tablets), the mean maximum concentration in peripheral leukocytes was 140 µg/mL. Concentrations remained above 32 µg/mL for approximately 60 hr. The mean half-lives for 6 males and 6 females were 34 hr and 57 hr, respectively. Leukocyte to plasma Cmax ratios for males and females were 258 (±77%) and 175 (±60%), respectively, and the AUC ratios were 804 (±31%) and 541 (±28%), respectively. The clinical relevance of these findings is unknown.

luminum- and magnesium-containing antacids reduce the peak serum levels (rate) but not the AUC (extent) of azithromycin (500 mg) absorption.

Administration of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin (500 mg) absorption.

A single oral dose of 1200 mg azithromycin (2 × 600 mg ZITHROMAX tablets) did not alter the pharmacokinetics of a single 800 mg oral dose of fluconazole in healthy adult subjects.

Total exposure (AUC) and half-life of azithromycin following the single oral tablet dose of 1200 mg were unchanged and the reduction in Cmax was not significant (mean decrease of 18%) by coadministration with 800 mg fluconazole.

A single oral dose of 1200 mg azithromycin (2 × 600 mg ZITHROMAX tablets) had no significant effect on the pharmacokinetics of indinavir (800 mg indinavir tid for 5 days) in healthy adult subjects